Skip to main
IFRX
IFRX logo

InflaRx (IFRX) Stock Forecast & Price Target

InflaRx (IFRX) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

InflaRx NV is positioned positively due to promising clinical results from its lead product candidate, vilobelimab, which has shown a significant 23.9% reduction in 28-day all-cause mortality, indicating strong efficacy in patient survival. The therapy's ability to reduce the need for corticosteroids and facilitate corticosteroid-free treatment in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) emphasizes its potential for practical application and demand. Additionally, post hoc analyses demonstrating substantial placebo-adjusted reductions in disease metrics further validate the therapeutic benefits of vilobelimab, supporting a favorable outlook for the company’s future performance and market position.

Bears say

InflaRx NV is currently experiencing depressed forward multiples, attributed primarily to prevailing market volatility. The company's cash burn remains a significant concern, as it may be heavily influenced by the stage of its development programs, with potential offsets from partner or collaborative revenue yet to materialize. Additionally, there is a lack of valuation assigned to commercial sales of GOHIBIC, as it is not recognized as a growth stage asset, contributing to projections of revenue generation that have largely remained stagnant.

InflaRx (IFRX) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of InflaRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About InflaRx (IFRX) Forecast

Analysts have given InflaRx (IFRX) a Buy based on their latest research and market trends.

According to 5 analysts, InflaRx (IFRX) has a Buy consensus rating as of Dec 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

InflaRx (IFRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.